Sarepta Therapeutics saw its share price dip on Thursday after regulators requested more work be done before approval of final-phase testing for a treatment for Duchenne muscular dystrophy. Analysts generally viewed the action of the U.S. Food and Drug Administration as a minor delay. SVB Leerink analyst Joseph Schwartz has maintained an outperform rating on … Continue reading “Sarepta Therapeutics Shares Crumble After Regulators Request More Work to Be Done”
Tag: srpt
Biotech & Pharma
Sarepta Therapeutics Announces Partnership With Roche to Sell Key Gene Therapy
Shares of Sarepta Therapeutics were gaining this week after Wall Street learned that the company…
December 25, 2019
Biotech & Pharma
The FDA Suddenly Approves This Drug From Sarepta Therapeutics
Shares of Sarepta Therapeutics were on the rise after the Food and Drug Administration (FDA)…
December 14, 2019
Biotech & Pharma
Sarepta Therapeutics Shares Collapse on Serious Duchenne Gene Therapy Complication
Shares of Sarepta Therapeutics fell as much as 13% on Thursday after Wall Street learned…
August 9, 2019